The aim of the @neurIST project is to create an IT infrastructure for the management of all processes linked to research, diagnosis and treatment development for complex and multi-factorial diseases. The IT infrastructure will be developed for one such disease, cerebral aneurysm and subarachnoid haemorrhage, but its core technologies will be transferable to meet the needs of other medical areas. Since the IT infrastructure for @neurIST will need to encompass data repositories, computational analysis services and information systems handling multi-scale, multi-modal information at distributed sites, the natural basis for the IT infrastructure is a Grid Service middleware. The project will adopt a service-oriented architecture because it aims to provide a system addressing the needs of medical researchers, clinicians and health care specialists (and their IT providers/systems) and medical supplier/consulting industries.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Correction to: Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50‑1 Yonsei‑Ro, Seodaemun‑Gu, Seoul, 03722 Republic of Korea.
[This corrects the article DOI: 10.1007/s13139-024-00847-4.].
View Article and Find Full Text PDFOn 'the Politics of Repair Beyond Repair': Radical Democracy and the Right to Repair Movement.
J Bus Ethics
May 2024
Science Policy Research Unit, University of Sussex, Falmer, UK.
This paper analyses the right to repair (R2R) movement through the lens of radical democracy, elucidating the opportunities and limitations for advancing a democratic repair ethics against a backdrop of power imbalances and vested interests. We commence our analysis by exploring broader political-economic trends, demonstrating that Original Equipment Manufacturers (OEMs) are increasingly shifting towards asset-based repair strategies. In this landscape, hegemony is preserved not solely through deterrence tactics like planned obsolescence but also by conceding repairability while monopolizing repair and maintenance services.
View Article and Find Full Text PDFPractical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Cancer
February 2025
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, USA.
Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and an emia (30%).
View Article and Find Full Text PDFPhoton mini-GRID therapy for preoperative breast cancer tumor treatment: A treatment plan study.
Med Phys
January 2025
Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.
Background: Breast cancer is the leading cause of female cancer mortality worldwide, accounting for 1 in 6 cancer deaths. Surgery, radiation, and systemic therapy are the three pillars of breast cancer treatment, with several strategies developed to combine them. The association of preoperative radiotherapy with immunotherapy may improve breast cancer tumor control by exploiting the tumor radio-induced immune priming.
View Article and Find Full Text PDFEnvironment scan of generative AI infrastructure for clinical and translational science.
Npj Health Syst
January 2025
Department of Population Health Sciences, Weill Cornell Medicine, New York, NY USA.
This study reports a comprehensive environmental scan of the generative AI (GenAI) infrastructure in the national network for clinical and translational science across 36 institutions supported by the CTSA Program led by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) at the United States. Key findings indicate a diverse range of institutional strategies, with most organizations in the experimental phase of GenAI deployment. The results underscore the need for a more coordinated approach to GenAI governance, emphasizing collaboration among senior leaders, clinicians, information technology staff, and researchers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!